metformin has been researched along with Thyroid Carcinoma, Anaplastic in 4 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Thyroid Carcinoma, Anaplastic: An aggressive THYROID GLAND malignancy which generally occurs in IODINE-deficient areas in people with previous thyroid pathology such as GOITER. It is associated with CELL DEDIFFERENTIATION of THYROID CARCINOMA (e.g., FOLLICULAR THYROID CARCINOMA; PAPILLARY THYROID CANCER). Typical initial presentation is a rapidly growing neck mass which upon metastasis is associated with DYSPHAGIA; NECK PAIN; bone pain; DYSPNEA; and NEUROLOGIC DEFICITS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the effect of metformin on growth of differentiated human thyroid cells, anaplastic thyroid carcinoma cells, a doxorubicin-resistant thyroid carcinoma cell line, and thyroid cancer stem cells." | 7.78 | Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. ( Chen, G; Derwahl, M; Renko, K; Xu, S, 2012) |
| "We investigated the effect of metformin on growth of differentiated human thyroid cells, anaplastic thyroid carcinoma cells, a doxorubicin-resistant thyroid carcinoma cell line, and thyroid cancer stem cells." | 3.78 | Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. ( Chen, G; Derwahl, M; Renko, K; Xu, S, 2012) |
| "Anaplastic cancer constitutes 1% of thyroid cancers, and it is one of the most aggressive cancers." | 1.56 | Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells. ( Biray Avci, C; Caliskan Kurt, C; Erdogan, M; Gunduz, C; Ozdemir Kutbay, N; Sarer Yurekli, B; Shademan, B, 2020) |
| "Anaplastic thyroid cancer cells were treated with 0-60 mM metformin for 24, 48 and 72 h." | 1.48 | Effects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines. ( Azizi, F; Hedayati, M; Mohammadi-Yeganeh, S; Nozhat, Z; Zarkesh, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Durai, L | 1 |
| Ravindran, S | 1 |
| Arvind, K | 1 |
| Karunagaran, D | 1 |
| Vijayalakshmi, R | 1 |
| Ozdemir Kutbay, N | 1 |
| Biray Avci, C | 1 |
| Sarer Yurekli, B | 1 |
| Caliskan Kurt, C | 1 |
| Shademan, B | 1 |
| Gunduz, C | 1 |
| Erdogan, M | 1 |
| Nozhat, Z | 1 |
| Mohammadi-Yeganeh, S | 1 |
| Azizi, F | 1 |
| Zarkesh, M | 1 |
| Hedayati, M | 1 |
| Chen, G | 1 |
| Xu, S | 1 |
| Renko, K | 1 |
| Derwahl, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules Size in Type 2 Diabetes: a 2-years Prospective Multicentric Study[NCT04298684] | Phase 4 | 90 participants (Anticipated) | Interventional | 2021-01-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for metformin and Thyroid Carcinoma, Anaplastic
| Article | Year |
|---|---|
Synergistic effect of metformin and vemurufenib (PLX4032) as a molecular targeted therapy in anaplastic thyroid cancer: an in vitro study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Humans; Metformin; | 2021 |
Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells.
Topics: AMP-Activated Protein Kinases; Apoptosis; Cell Line, Tumor; Drug Therapy, Combination; Gene Expressi | 2020 |
Effects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug | 2018 |
Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.
Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle; Cell D | 2012 |